GleamWall
中文EN

CYDY CytoDyn Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1175680 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-171.6%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-351.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets614.7%
Debt / equity—
Current ratio0.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-212.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-05-31FY20252025-05-31
Income statement
Revenue——
SG&A expense$7.45M$7.26M
Operating income-$38.58M$9.66M
Pretax income-$42.70M$3.75M
Income tax$0$0
Net income-$42.70M$3.75M
EBITDA-$38.56M$9.68M
EPS (basic)-0.030.00
EPS (diluted)-0.030.00
Weighted avg. shares (diluted)1.29B1.24B
Balance sheet
Cash & equivalents$11.85M$11.90M
Current assets$13.88M$17.88M
Total assets$13.97M$18.05M
Current liabilities$53.73M$70.52M
Long-term debt$38.34M$45.35M
Total debt$38.34M$45.35M
Total liabilities$123.69M$114.09M
Shareholders' equity-$109.72M-$96.04M
Net debt$26.49M$33.45M
Shares outstanding1.37B1.25B
Cash flow statement
Operating cash flow-$17.25M-$8.77M
Investing cash flow$0$0
Financing cash flow$17.20M$10.85M
Depreciation & amortization$17,000$18,000
Stock-based compensation$1.63M$1.61M

Free plan shows the latest 2 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.